drugset / Trial / NCT06165614

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

NCT06165614

NaSingle-groupOpen-labelTreatment

Summary

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

Timeline

Start
2024-03-04
Primary completion
2025-01-30
Completion
2025-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 200 mg Other